MRD Response and Prognosis With Venetoclax + Azacitidine in Patients With AML Ineligible for Intensive Induction Chemotherapy From the VIALE-A Trial

June 4-8, 2021; Online at https://conferences.asco.org/am
Among patients with CR/CRi on venetoclax + azacitidine, achieving MRD <10-3 was associated with longer duration of response, event-free survival, and overall survival, regardless of when MRD negativity was attained.
Format: Microsoft PowerPoint (.ppt)
File Size: 531 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue